ISPOR - PCN144 The Comparative Pharmacoeconomic Analysis of Using Cabozantinib As Second-LINE Therapy for Adult Patients with Metastatic Renal Cell Carcinoma in Russia

PCN144 The Comparative Pharmacoeconomic Analysis of Using Cabozantinib As Second-LINE Therapy for Adult Patients with Metastatic Renal Cell Carcinoma in Russia

Abstract

Authors

V. Krysanova I. Krysanov V. Ermakova

Full Text Cite This Article

Back to Volume 23, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now